Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Relevium Technologies Inc. (RLLVF)
Montreal, QC, CA
Relevium Technologies Inc. operates within the health and wellness sector, focusing on identifying, assessing, acquiring, and managing various brands and businesses, primarily through e-commerce channels. The company distributes a range of products, including dietary supplements, nutraceuticals, sports nutrition items, and cosmeceuticals, mainly through its Bioganix online brand. It also offers dietary supplements under the LeefyLyfe label and skincare solutions marketed as the Push & Pull System. Additionally, Relevium has developed specialized lines such as Relevium Senior, aimed at older adults for inflammatory conditions affecting joints, heart, and brain, and Relevium Kids, providing nutraceuticals and oral nutritional supplements for children. Headquartered in Montreal, Canada, the company was formerly known as BIOflex Technologies Inc. until it rebranded to Relevium Technologies Inc. in December 2015.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +5,900.00% | -78.57% | -96.25% | -96.25% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Medical - Pharmaceuticals: +7.8%-69.3% Q1'21: -56.7% (vs Q1'20)
-
EPS growth Medical - Pharmaceuticals: +20.2%+30.2% ★ Q1'21: -4,250.6% (vs Q1'20)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%-421.8% Q1'21: +0.0% (vs Q1'20)
-
EBIT margin Medical - Pharmaceuticals: +6.8%-505.4% Q1'21: -140.8% (vs Q1'20)
-
ROIC Medical - Pharmaceuticals: +6.1%— Q1'21: +1,636.2% (vs Q1'20)
-
Share dilution Medical - Pharmaceuticals: +0.0%+10.7% Q1'21: +42.3% (vs Q1'20)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×-0.69× Q1'21: -1.62× (vs Q1'20)
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Aurelio Useche | President, Chief Executive Officer & Director | 133.2K | male |
| Mark Anthony Billings | Chief Financial Officer | 46.2K | male |
| Abis Hussain | Senior Marketing Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for RLLVF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
